Cobenfy Panel
In September 2024, the Food and Drug Administration (FDA) approved the first novel medication for schizophrenia in nearly two decades. With the widespread interest around this new drug, Cobenfy, questions have been raised by providers and patients alike about how the drug works and what it means for the future of psychosis treatment. This panel will bring together experts with backgrounds in research, lived experience, and pharmacy to discuss Cobenfy and its potential impact on psychiatry.
▶︎
How to Permanently Cure Bipolar Disorder. And what to do while we wait
▶︎
How America Is Losing the World | Lunch Money with Paul Krugman and Heather Cox Richardson
▶︎
Three Deadly Errors: How to Avoid Benzodiazepine-Induced Brain Damage
▶︎
Conan O’Brien Delivers the Commencement Address | Harvard Commencement 2026
▶︎
🫀 2025 BLS Practice Test | CPR & AED Practice Test with Detailed Answers
▶︎
Antidepressant Tier List: Best vs Worst (My Honest Take)
▶︎
May 2026 - Research Spotlight with Dr. DeMayo and Dr. Sochet
▶︎
7/15/25 - Neurobiology & Recovery: Addressing Nicotine Use Among Ind. with Serious Mental Illness
▶︎
Being polite - soften your language: Live English Class
▶︎
Complex Regional Pain Syndrome | AANS/CNS | Pisapia, Rizk, Siddiqui
▶︎
Dr. Thomas Mather a.k.a The TickGuy Shares Tick Prevention Tips | The Daily Show
▶︎
Israel on trial | feat. Roy K. Altman
▶︎
Psychosis & Schizophrenia Mnemonics (Memorable Psychiatry Lecture)
▶︎
PASS Your Phlebotomy Exam! 💉 Must-Know Terms + Practice Questions
▶︎
Long-Term Effect of Electroconvulsive Therapy (ECT) on the Brain
▶︎
What to do when you don't understand: Live English class
▶︎
ACLS Drugs Review with Nurse Eunice 📚💉
▶︎
Python Variables | Python Operators | Python Tutorial For Beginners | Intellipaat
▶︎
Medical Cannabis and MS: A Neurologist's Perspective
▶︎